Drug Discovery and Pharmaceutical Chemical Development Expert

Technical Consultant #1968

A Medicinal Chemist with an extensive and diversified background in drug discovery.
Discovery of a smallpox inhibitor utilized in major biodefense agencies.
Computer aided drug design and creative applications of organic chemistry.
Implements and manages database solutions and robotic applications.

Key Competencies

CMC and IND support.
Drug discovery.
Chemical development.
Establishing and managing robotic solutions.
Managing complex scientific instruments.
Team leadership and coordination, building effective project teams.
Implementing and managing database solutions.
NMR (Nuclear Magnetic Resonance), FT-IR (Fourier Transform Infrared Spectroscopy), GC/MS (Gas Chromatography - Mass Spectrometry), LC/MS (Liquid chromatography - Mass Spectrometry), HPLD, (High-Performance Liquid Chromatography).
Using organic chemistry to solve synthetic problems.
Molecularly targeted approach.
Establishing and managing robotic applications.
Computer-assisted drug design.

Undisclosed Company, Medicinal Chemist Consultant (Owner), 2011 - Present

Oversees early drug discovery and source manufacture of API and write chemistry CMC's.
Establish infrastructure and screening libraries for start-up businesses provide preclinical support.
Evaluate SAR and support sale of specific intellectual property for ViroPharma.
Manage manufacturing of clinical candidate API, provide virtual chemical development, and support IP legal.
Serve on Scientific Board of Advisors for Combs Laboratories LLC.

Cephalon, Inc., West Chester, PA, 2004 - 2011

Senior Scientist II - Chemistry Administration, 2009 - 2011

Responsible for Chemistry Administration.
Identified and implemented Dotmatics and ChemInventory, key departmental software tools.
Oversaw group and responsible for supporting chemistry activities such as registration, and storing proprietary compounds, dispensing chemical procurement and inventory, equipment and supplies.
Supported the management of SAI Advantium an outsourced chemistry collaboration.
Proposed and executed scaffolds that provided novel IP for existing products.
Expertly managed automation including bringing robotics on line and on time.

Senior Scientist II CNS, 2004 - 2009

Oversaw CNS lead optimization that directed target selection.
Led three scientists performing CNS candidate selection.
Member of successful H3 project team delivering potent inverse agonist clinical candidate.
Led group that delivered proof of concept for the 5-HT6 receptor antagonist project.
Calculated target drug-like properties for CNS projects.

Viropharma, Exton, PA, 1995 - 2004

Fellow, Principal Scientist and Senior Scientist - Department of Medicinal Chemistry

Managed seven chemists, three Ph.D.s and four associates and oversaw orthopox inhibitor program.
Invented a smallpox drug which was selected by U.S. government resulting in a bid of $433 million.
Headed "hit-to-lead" in discovery, identifying investigation hits in viral projects and moving toward decision.
Identified all Hepatitis C leads being pursued with three entering clinics with VP-796 (HCV pol) demonstrating proof of concept in Phase II.
Identified new lead series in HCV pol, orthopox and viral hemorrhagic fever.
Led group that identified and directed synthesis of first hepatitis C polymerase inhibitor that advanced to Phase II clinical trials.
Managed Hepatitis C alliance with Wyeth-Ayerst as coordinating chemistry between the two groups.
Advanced compounds to lead status through the coordination of biology, chemistry, DMPK, analytic and outside parties.
Supported drug discovery through selection of ActivityBase for corporate database and ACD's chemical property prediction software.
Acquired over 300,000 new chemical entities.
Recruited and hired chemists and established departmental budget as acting director.

Sterling Winthrop, Inc. - Sanofi Winthrop, Inc., NY and PA, 1985 - 1995

Filling the rolls: Principal Research Investigator, Senior Research Investigator, Senior Research Chemist for the Department of Medicinal Chemistry.
Designed potent inhibitor, which led to NDA candidate Pleconaril and identified back-ups by identifying bioisosteres to isoxazole functionality using x-ray crystallography and computer-assisted design.
Identified promising hits as project chemist for Herpes and HIV Tat and Rev programs , and selected compounds for screening, planned synthetic approaches to targeted mechanisms, synthesized where appropriate, interpreted SAR, and presented findings.
Developed convenient palladium catalyzed method for generating heterobiaryls which was widely cited after publication and found widespread use in several Sterling projects.
Responsible for bar coding and managerial oversight of chemical inventory.

Credentials

Academic and Professional Affiliations

Publications and Patents